EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab

Yasunori Yoshino, Akiko Furusawa, Katsuhiko Nara, Ayumi Taguchi iD, Masako Ikemura, Hideo Arai, Tsubasa Hiraki, Aya Ishizaka, Saki Tsuchimochi, Harunori Honjoh, Naoyuki Miyasaka, Yasuyuki Hirashima und 2 weitere

Cancer · 2025

DOI: 10.1002/cncr.70071 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Yasunori Yoshino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Ovarian Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bridging the Gap Between R&d and the IDeal society, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platinum‐resistant (PR) ovarian clear cell carcinoma (OCCC) is highly resistant to chemotherapy and has a poor prognosis. Both in‐vitro and clinical studies have suggested that gemcitabine (GEM) is particularly effective against OCCC. Moreover, a combination with bevacizumab (Bev) is expected to enhance the efficacy of chemotherapy.

Methods

To clarify these effects, the authors conducted a multicenter, retrospective cohort study of 130 patients who received treatment single‐agent chemotherapy, with or without Bev, for PR‐OCCC. The effects of loss of AT‐rich interaction domain 1A (ARID1A) protein expression also were assessed.

Results

Patients who received GEM as their first regimen achieved better overall survival (OS) than those who received other agents (median OS, 15.2 vs. 11.0 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.41–0.96; p = .032). Bev combination therapies demonstrated a significantly improved time to treatment failure compared with chemotherapy alone (6.6 vs. 2.7 months; HR, 0.61; 95% CI, 0.41–0.87; p = .009) and showed a trend toward longer OS (23.3 vs. 9.8 months; HR, 0.62; 95% CI, 0.34–1.05; p = .085). ARID1A status did not affect OS in the overall group or in the group that received GEM as the first‐line regimen ( p = .41 and p = .31, respectively).

Conclusions

Collectively, the current findings suggest that GEM, particularly as a first‐line treatment, may improve the prognosis of patients with PR‐OCCC. Moreover, Bev combination therapy is a promising option for treating PR‐OCCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineOvarian NeoplasmsBevacizumabAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmAdenocarcinoma, Clear CellHumansFemaleGemcitabineMiddle AgedRetrospective StudiesAgedAdultTranscription FactorsTreatment OutcomeDNA-Binding ProteinsPrognosis

Stichwörter der Autor:innen

AT‐rich interaction domain 1A (ARID1A)bevacizumabgemcitabineovarian clear cell carcinomaplatinum resistance

Substanzen

GemcitabineDeoxycytidineBevacizumabARID1A protein, humanTranscription FactorsDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Gynecology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
  • Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
  • Department of Pathology, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Ayumi Taguchi

Förderung

  • Bridging the Gap Between R&d and the IDeal society
  • Japan Society for the Promotion of Science

Zitieren

APA

Yoshino, Y., Furusawa, A., Nara, K., Taguchi, A., Ikemura, M., Arai, H., Hiraki, T., Ishizaka, A., Tsuchimochi, S., Honjoh, H., Miyasaka, N., Hirashima, Y., Sone, K., & Kino, N. (2025). Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab. Cancer. https://doi.org/10.1002/cncr.70071

Vancouver

Yoshino Y, Furusawa A, Nara K, Taguchi A, Ikemura M, Arai H, et al. Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab. Cancer. 2025. doi:10.1002/cncr.70071

BibTeX
@article{Yoshino2025,
  author = {Yoshino, Yasunori and Furusawa, Akiko and Nara, Katsuhiko and Taguchi, Ayumi and Ikemura, Masako and Arai, Hideo and Hiraki, Tsubasa and Ishizaka, Aya and Tsuchimochi, Saki and Honjoh, Harunori and Miyasaka, Naoyuki and Hirashima, Yasuyuki and Sone, Kenbun and Kino, Nao},
  title = {Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70071}
}
Kostenlos starten →